The present disclosure relates to an anti-CD79B antibody, the antigen-binding fragment thereof, and the pharmaceutical use thereof. Further, the present disclosure relates to a chimeric antibody, a humanized antibody including the CDR region of the anti-CD79B antibody, and a pharmaceutical composition comprising the human anti-CD79B antibody or antigen-binding fragment thereof, and use thereof as an anticancer drug. In particular, the present disclosure relates to the use of the humanized anti-CD79B antibody in the manufacture of a medicament for the treatment of lymphomas, such as DLBCL.本公開涉及抗CD79B抗體、其抗原結合片段及其醫藥用途。進一步地，本公開涉及包含該抗CD79B抗體CDR區的嵌合抗體、人源化抗體，以及包含人抗CD79B抗體或其抗原結合片段的醫藥組成物，以及其作為抗癌藥物的用途。尤其地，本公開涉及一種人源化的抗CD79B抗體，在製備治療淋巴瘤(如DLBCL)的藥物中的用途。
